ArticleIndian journal of community medicine : official publication of Indian Association of Preventive & Social Medicine
A Clinico-Demographic Study of Mucormycosis Cases Admitted in a Tertiary Care Government Hospital in Western Maharashtra.
Article in Indian journal of community medicine : official publication of Indian Association of Preventive & Social Medicine. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Mucormycosis, caused by filamentous fungi, is a rare but potentially fatal fungal infection associated with high morbidity and mortality. The COVID-19 pandemic has brought renewed attention to this infection, with an increasing number of cases worldwide. To study the clinico-demographic characteristics and their association with outcomes in mucormycosis cases. A tertiary care government hospital in Western Maharashtra. A Descriptive Cross-Sectional study. Methodology: The study was conducted in a tertiary care hospital analyzing information from all cases of mucormycosis admitted between January 2021 and December 2022. Data were collected from the medical record section encompassing demographic details, clinical features, treatment, and outcome. Proportion, standard deviation, Chi-square test were used to analyze data by using Microsoft Excel. Results: Demographic analysis revealed a predominance of males 66.67%, and rural residents 73.53% among the mucormycosis cases. Co-morbidities were prevalent in 71.57% cases. The most common clinical presentation was rhino-orbital-cerebral mucormycosis (91.67%). Cortico-steroid use was seen in 58.82% cases. Among 270 cases, the case fatality rate was 24.45%. Older age, co-morbidities, COVID-19 status, delayed diagnosis, and delay in treatment were significantly associated with mortality. Conclusions: Demographic, clinical, and treatment-related factors influence mucormycosis outcome. Early diagnosis, aggressive treatment, and management of co-morbidities can mitigate morbidity and mortality associated with mucormycosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.